Immutep’s Growth and Advancements Boost Market Visibility
Company Announcements

Immutep’s Growth and Advancements Boost Market Visibility

Immutep (IMMP) has released an update.

Immutep Limited has reported significant progress in its clinical trials, including positive outcomes from the TACTI-003 Phase IIb trial for first-line head and neck cancer and successful dosing in the first human trial of IMP761 for autoimmune diseases. The company has been added to the S&P ASX300 Index, highlighting its growth and market visibility. Additionally, Immutep maintains a robust financial position with cash reserves of A$172.3 million, ensuring operational stability through to the end of 2026.

For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmutep reports Q1 cash receipts from custmers $20,000
TheFlyImmutep announces first-in-human phase I study of IMP761
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App